Orphanet Journal of Rare Diseases | Multicenter Retrospective Study of Chronic Inflammatory Arthritis in 22q11 Deletion Syndrome

Recommend:

This study is the first systematic description of clinical features in 30 patients with 22q11 deletion syndrome (22q11DS) and concurrent chronic inflammatory arthritis, revealing significant differences in immunological and clinical manifestations compared to traditional juvenile idiopathic arthritis (JIA). It emphasizes the possibility of 22q11DS-associated arthritis as an independent clinical entity, providing critical insights for clinical diagnosis and treatment.

 

Literature Overview
The article titled 'Chronic inflammatory arthritis in 22q11.2 deletion (DiGeorge) syndrome: a multicentric study', published in the Orphanet Journal of Rare Diseases, reviews and summarizes the clinical characteristics, diagnosis, and treatment of chronic inflammatory arthritis in patients with 22q11 deletion syndrome (22q11DS). Based on retrospective data from multiple pediatric centers, the study analyzed 30 cases diagnosed between 1992 and 2024. The paper further explores the immune deficiency mechanisms of the syndrome and their potential link to autoimmune diseases, highlighting differences from traditional juvenile idiopathic arthritis (JIA) and offering new perspectives for clinical identification and management.

 

Assesses the pathogenic potential of gene variants, providing reference for functional analysis.

Learn More

 

Study Methods and Design
The study employed a multicenter retrospective design, collecting clinical data of 30 patients with confirmed 22q11 deletion syndrome (22q11DS) and chronic arthritis from 9 international pediatric centers via email surveys. Inclusion criteria required molecular diagnosis of 22q11DS, arthritis onset before age 16, and duration exceeding 6 weeks, with exclusion of cases attributable to other known causes. Collected data included age at diagnosis, joint involvement, laboratory markers, treatment regimens, and infection history. Descriptive statistical analyses were performed, including mean, median, frequency, and range.

Key Findings and Perspectives

• Of the 30 patients, 21 (70%) were female, with a median age at arthritis onset of 3 years, and median number of involved joints was 4.5 (range 1–25).
• 50% of patients presented with polyarticular arthritis, most commonly affecting the knee (86.7%), followed by the ankle (60%), with only one case of uveitis reported.
• Most patients showed elevated ESR (72%) and CRP (83.3%), with 63.3% testing positive for ANA, while RF and CCP antibodies were universally negative.
• Treatment included methotrexate (66.7%), biologics (56.7%), and corticosteroids (53.3%), with infections mostly mild respiratory tract infections.
• Follow-up showed 53.3% of patients remained active, 78.6% of those in remission still required medication, and 40% developed radiographic joint damage.
• Patients treated with biologics after 2000 showed fewer joint involvements compared to those before 2000 (average 5.8 vs 8.4 joints).

Implications and Future Directions
This study provides the first systematic analysis of clinical and immunological features of chronic arthritis in 22q11DS, suggesting it may represent a distinct autoimmune manifestation of the syndrome rather than traditional JIA. Early biologic use may improve disease control. Prospective studies are needed to validate pathogenic mechanisms, optimize treatment strategies, and assess long-term outcomes.

 

Input a gene to view its associated signal pathways and known upstream/downstream molecules, facilitating pathway analysis.

Learn More

 

Conclusion
This retrospective analysis of 30 patients with 22q11 deletion syndrome and chronic arthritis revealed a unique clinical and immunological phenotype: early onset, polyarticular involvement, elevated inflammatory markers, negative RF/CCP, and rare uveitis. These features distinguish them significantly from traditional juvenile idiopathic arthritis (JIA), suggesting that 22q11DS-associated arthritis may represent a distinct disease entity. The study also showed that, despite intensive treatment including methotrexate and biologics, most patients remained active, and joint damage was common. This underscores the importance of early identification and aggressive intervention in such patients. Additionally, the study highlights the complex interplay between immunodeficiency and autoimmunity, including reduced T cell receptor diversity, impaired regulatory T cell function, and B cell homeostasis imbalance, providing directions for future mechanistic research. This study offers critical data for clinicians managing arthritis in 22q11DS patients and provides potential application context for rare disease platform tools such as gene variant analysis and signal pathway querying, aiding further research into pathogenesis and treatment optimization.

 

Emily Liebling, Caroline Freychet, Valentina Guarnieri, Gabriele Simonini, and Teresa Giani. Chronic inflammatory arthritis in 22q11.2 deletion (DiGeorge) syndrome: a multicentric study. Orphanet Journal of Rare Diseases.